tradingkey.logo

Nyxoah SA

NYXH
4.790USD
-0.060-1.24%
收盘 12/22, 16:00美东报价延迟15分钟
179.84M总市值
亏损市盈率 TTM

Nyxoah SA

4.790
-0.060-1.24%

关于 Nyxoah SA 公司

Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.

Nyxoah SA简介

公司代码NYXH
公司名称Nyxoah SA
上市日期Sep 18, 2020
CEOTaelman (Olivier)
员工数量- -
证券类型Ordinary Share
年结日Sep 18
公司地址Rue Edouard Belin 12
城市MONT-SAINT-GUIBERT
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Belgium
邮编1435
电话3226121755
网址https://www.nyxoah.com/
公司代码NYXH
上市日期Sep 18, 2020
CEOTaelman (Olivier)

Nyxoah SA公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Robert Taub
Mr. Robert Taub
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
4.31M
+1.65%
Mr. John Landry
Mr. John Landry
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Maurits S. Boon
Dr. Maurits S. Boon
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Loic Moreau
Mr. Loic Moreau
President - International
President - International
--
--
Mr. Olivier Taelman
Mr. Olivier Taelman
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Virginia Kirby
Ms. Virginia Kirby
Independent Director
Independent Director
--
--
Mr. Christoph Eigenmann
Mr. Christoph Eigenmann
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Rita F. Johnson-Mills
Ms. Rita F. Johnson-Mills
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Pierre Gianello, M.D.
Dr. Pierre Gianello, M.D.
Non-Executive Director
Non-Executive Director
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Robert Taub
Mr. Robert Taub
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
4.31M
+1.65%
Mr. John Landry
Mr. John Landry
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Maurits S. Boon
Dr. Maurits S. Boon
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Loic Moreau
Mr. Loic Moreau
President - International
President - International
--
--
Mr. Olivier Taelman
Mr. Olivier Taelman
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Virginia Kirby
Ms. Virginia Kirby
Independent Director
Independent Director
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 12月6日 周六
更新时间: 12月6日 周六
持股股东
股东类型
持股股东
持股股东
占比
Cochlear Limited
13.59%
Taub (Robert)
10.02%
Monden (Anneliese)
6.83%
Gilde Healthcare Partners B.V.
6.83%
ResMed Inc
4.02%
其他
58.72%
持股股东
持股股东
占比
Cochlear Limited
13.59%
Taub (Robert)
10.02%
Monden (Anneliese)
6.83%
Gilde Healthcare Partners B.V.
6.83%
ResMed Inc
4.02%
其他
58.72%
股东类型
持股股东
占比
Individual Investor
19.98%
Corporation
17.61%
Venture Capital
6.83%
Investment Advisor/Hedge Fund
5.88%
Investment Advisor
3.90%
Hedge Fund
0.63%
Research Firm
0.17%
其他
45.02%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
74
8.21M
21.94%
-2.04M
2025Q2
69
25.16M
67.22%
-3.01M
2025Q1
70
26.40M
70.53%
-2.65M
2024Q4
73
25.60M
68.47%
-1.01M
2024Q3
72
23.51M
71.46%
-828.78K
2024Q2
72
23.54M
72.39%
-1.11M
2024Q1
64
20.89M
72.68%
+374.51K
2023Q4
59
21.08M
73.36%
-418.05K
2023Q3
66
19.86M
69.10%
-2.56M
2023Q2
66
20.66M
78.20%
+1.01M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Cochlear Limited
5.63M
15.05%
--
--
Aug 29, 2025
Taub (Robert)
3.98M
10.62%
+585.48K
+17.27%
Dec 31, 2024
Monden (Anneliese)
2.94M
7.86%
--
--
Dec 31, 2024
Gilde Healthcare Partners B.V.
2.94M
7.85%
--
--
Dec 31, 2024
ResMed Inc
1.73M
4.62%
--
--
Dec 31, 2024
Hambrecht (Jürgen)
1.34M
3.59%
--
--
Dec 31, 2024
Vestal Point Capital, LP
1.11M
2.98%
-288.43K
-20.57%
Sep 24, 2025
BNP Paribas Asset Management Belgium S.A.
742.38K
1.98%
--
--
Aug 31, 2025
BlackRock Financial Management, Inc.
683.64K
1.83%
-281.93K
-29.20%
Jun 30, 2025
Medical Strategy GmbH
340.00K
0.91%
--
--
Jul 31, 2025
查看更多

持股ETF

更新时间: 12月2日 周二
更新时间: 12月2日 周二
机构名称
占比
iShares Health Innovation Active ETF
0.09%
Avantis International Equity ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
SPDR Portfolio Europe ETF
0%
DFA Dimensional International Small Cap ETF
0%
Avantis International Small Cap Equity ETF
0%
iShares Health Innovation Active ETF
占比0.09%
Avantis International Equity ETF
占比0%
DFA Dimensional International Core Equity 2 ETF
占比0%
SPDR Portfolio Europe ETF
占比0%
DFA Dimensional International Small Cap ETF
占比0%
Avantis International Small Cap Equity ETF
占比0%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

Nyxoah SA的前五大股东是谁?

Nyxoah SA 的前五大股东如下:
Cochlear Limited持有股份:5.63M,占总股份比例:15.05%。
Taub (Robert)持有股份:3.98M,占总股份比例:10.62%。
Monden (Anneliese)持有股份:2.94M,占总股份比例:7.86%。
Gilde Healthcare Partners B.V.持有股份:2.94M,占总股份比例:7.85%。
ResMed Inc持有股份:1.73M,占总股份比例:4.62%。

Nyxoah SA的前三大股东类型是什么?

Nyxoah SA 的前三大股东类型分别是:
Cochlear Limited
Taub (Robert)
Monden (Anneliese)

有多少机构持有Nyxoah SA(NYXH)的股份?

截至2025Q3,共有74家机构持有Nyxoah SA的股份,合计持有的股份价值约为8.21M,占公司总股份的21.94%。与2025Q2相比,机构持股有所增加,增幅为-45.28%。

哪个业务部门对Nyxoah SA的收入贡献最大?

在--,--业务部门对Nyxoah SA的收入贡献最大,创收--,占总收入的--%。
KeyAI